Genetic forms of sensorineural deafness account for almost half of all patients with hearing loss (Shearer et al., 2011) . Current therapies for sensorineural hearing loss are based primarily on amplification with hearing aids or, if the deficit is severe to profound, surgical placement of cochlear implants. In recent years, a large and ever increasing number of genes whose mutations cause human deafness have been identified, thereby drastically enhancing the diagnostic capabilities for individuals with hearing loss (Lenz and Avraham, 2011) . Knowledge of the underlying molecular genetic mechanisms that cause hearing loss also raises the possibility for novel therapeutics, such as those based on gene transfer and related methods that influence gene expression in affected tissues. For example, replacement of a defective or absent gene product, or removal and/or repair of products of dominant negative mutations, might be predicted to correct the underlying pathologies caused by specific gene mutations. A successful approach for the latter type of therapy was recently accomplished for a dominant-negative mutation of the GJB2 gene, which encodes the gap junction protein Connexin 26 (Cx26) (Maeda et al., 2005; Richard et al., 1998) . Maeda et al. (2005) showed that siRNA-mediated downregulation of this dominant-negative GJB2 mutation partially improved hearing in mouse ears that model this mutation. These earlier studies on Cx26 showed that manipulation of a mutant protein can be achieved without compromising optimal levels of the normal protein, a critical requirement for successful translation of this approach to humans. Now there is evidence presented by Akil et al. (2012) in this issue of Neuron that further supports the promise of gene therapy approaches to improving hearing health. Unlike the Maeda study that used a mouse model of a dominantnegative mutation, Akil et al. (2012) report a pioneering treatment of a mouse with a gene deletion (Seal et al., 2008) . They show that replacement of an absent gene (VGLUT3) by viral-mediated insertion of the wild-type gene into VGLUT3 knockout mouse ears can rescue structural and functional hearing loss phenotypes. Results presented in their paper are a true breakthrough because they show that gene therapy can lead to functional recovery from sensorineural deafness. Even more exciting is the direct relevance of this work to a large population of humans who have mutations in the VGLUT3 gene (Ruel et al., 2008) .
Vglut3 encodes a vesicular glutamate transporter that is essential for transporting the neurotransmitter glutamate into secretory vesicles (Takamori et al., 2002) . In mice lacking VGLUT3 in the inner hair cells, hearing is absent because the neurotransmitter glutamate is not released by inner hair cells and auditory neurons do not depolarize in response to sound (Seal et al., 2008) . Akil et al. (2012) used adeno-associated virus type 1 (AAV1) to insert the wild-type mouse Vglut3 gene into cochlear cells (Figure 1 ). Interestingly, after viral infection, most cells in the cochlea expressed the green fluorescent protein (GFP) reporter construct, whereas only hair cells expressed the newly introduced VGLUT3 protein. Infected ears demonstrated nearly complete rescue of auditory function, based on electrophysiological measurements by auditory brainstem response (ABR). Significant yet partial improvement was also noted in the morphology of the synaptic region as well as in other physiological and behavioral measures of hearing, predicting potentially exciting future clinical benefits. Morphological rescue of the synaptic ribbon area, where inner hair cells connect with auditory nerve terminals, provided a possible structural explanation for the accompanying functional improvement ( Figure 1 ). Mutant mice without treatment also displayed a partial degeneration of auditory neurons. AAV1-VGLUT3 treatment did not prevent this degeneration, but remaining auditory neurons were nevertheless sufficient to facilitate adequate hearing thresholds. Long-term follow-up of infected ears showed that rescue of hearing ability was stable until a relatively late age in the mice (9 months), suggesting that the therapy may result in permanent structural and functional repair.
Application of gene replacement therapy to treatment of deafness appears relatively simple and attractive for several reasons. Introduction of the normal (wildtype) protein into hair cells, in which its function is critical for hearing (and its absence causes deafness), is a compelling approach for effectively and permanently treating genetic forms of deafness. Such approaches have been under consideration for some time, with phenotypic rescue for deafness by gene replacement first shown in 1998, when researchers rescued the DFNB3 deafness mouse model using germline insertion of a bacterial artificial chromosome (BAC) with the wild-type gene (Probst et al., 1998) . However, transgenic methods such as BAC insertion are not feasible in humans, for both practical and ethical reasons. In contrast, the approach used by Akil et al. (2012) is conceptually relevant to clinical applications. Theoretically, viral infection for inserting a wild-type gene could be used to reverse mutant phenotypes when hair cells or other critical cell populations survive yet do not function normally, such as with VGLUT3 mutations in humans and mice.
Several technical advances have been made in this study that put us closer to seeing successful gene therapy in humans. Use of AAV apparently provides long-term expression, with minimal or no side effects attributed to viral infection. Expression of the reporter gene, GFP, occurred throughout the infected cochlear tissue but VGLUT3 expression was restricted to inner hair cells, suggesting that posttranslational mechanisms can act on exogenously introduced DNA to regulate tissue-specific gene expression. The broader implications of this precise level of gene regulation are that concerns about tissue or cell typespecific targeting may be more easily overcome than previously suspected. A key concern associated with viralmediated gene transfer is gene dosage, because the amount of gene product produced and the extent to which the cell can regulate it may vary widely. Results by Akil et al. (2012) suggest that the levels of VGLUT3 produced by the AAV were compatible with phenotypic rescue, providing hope that adequate levels of protein synthesis may be achieved in humans by this method. However, gene products relevant for other gene mutations may be more sensitive to gene dosage, such that gene replacement therapy strategies will need to be developed specifically for each mutation.
Despite the excitement raised by this study, several milestones will need to be reached before this approach can be used in humans. First, proof that this method works in mature ears needs to be provided. Akil et al. (2012) used mouse pups that were 1-3 or 10-12 days old, both ages in which the mouse auditory system is still immature. The researchers determined that the phenotypic rescue worked better in the younger mice, which may suggest that the current method is less effective in truly mature tissues (P21 and later for the mouse cochlea). The decreased efficacy in older animals could reflect the maturity of hair cells or surrounding cells and tissues (leading to reduced plasticity), development of immune memory, or as-yet-undefined changes in the inner ear. Second, for applicability to human therapies, it may be necessary to correct most if not all aspects of the relevant underlying pathologies causing the deafness. For example, Akil et al. (2012) observed ongoing loss of spiral ganglion neurons, despite functional and structural improvements in the treated hair cells. Ongoing neuronal degeneration would probably degrade long-term correction of inner ear defects and would need to be addressed for optimal treatment of patients with VGLUT3 mutations.
Despite these limitations, the possibilities raised by this study warrant high enthusiasm. For individuals with hereditary hearing loss who are currently treated with cochlear implants, there is reason to Figure 1 
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The typical inner hair cell connects to auditory nerve fibers and depolarizes them by releasing glutamate upon sound activation. Shown to the right of the hair cell are schematic drawings of the ribbon synapse as seen by electron microscopy. In Vglut3 mutant mice, VGLUT3 is absent, the ribbon and neurotransmitter vesicles appear pathological (the ribbon is flat and vesicles are elongated), and hearing is impaired (the musical notes depict hearing ability or lack thereof). In Vglut3 mutant mice treated with AAV1-mediated Vglut3 gene transfer, VGLUT3 can be detected in inner hair cells, and both the ribbon and the vesicles more closely resemble the normal morphology. Mice treated with AAV-Vglut3 exhibit normal hearing thresholds as measured by electrophysiology and also exhibit hearing using behavioral assays.
believe that approaches like this could lead to the development of significantly better, more specifically targeted therapies to correct their hearing. Gene therapy-based approaches will probably become relevant to genetic forms of hearing loss in which the underlying cells or proteins can be identified, especially in cases in which critical cells and tissues survive until the age at which gene transfer protocols can be used. It would be truly groundbreaking if similar phenotypic rescue could be developed to treat some of the more common forms of hereditary deafness, such as those caused by the most prevalent forms of Connexin gene mutations, which collectively account for more than half of all cases of human hereditary deafness (Cryns and Van Camp, 2004) . It is also reasonable to predict that the successful treatment approach reported in the VGLUT3 deafness mouse model could establish a framework for assessing the potential for gene replacement therapies for other senses and other hereditary neurological disorders. Finally, the results of this study may also help pave the way for personalized, gene-informed, targeted therapies that improve health for individuals with other Mendelian disorders. In case you have not heard, the future is now.
In a theoretical study in this issue of Neuron, Gidon and Segev (2012) identify several new principles governing how inhibition interacts with excitation in active dendrites. They show that inhibitory synapses can interact with excitability at a distance, effectively ''throwing their voices'' in the dendritic tree, such that distributed inhibitory synapses can act synergistically to provide a global veto of dendritic excitability.
The interplay between inhibition and excitation has fascinated neurophysiologists at least since Sherrington (1932) proposed that it forms the basis of the operation of the nervous system. Over the last 80 years, numerous functional roles have been proposed for inhibition, including regulation of timing, gain control, sharpening of tuning, and stabilization of ongoing activity in recurrent neural circuits (Isaacson and Scanziani, 2011) . In addition, anatomical evidence has accumulated showing that principal neurons receive thousands of inhibitory synaptic contacts, made by distinct subtypes of inhibitory interneurons which target specific domains on the dendritic tree and which may also have distinct functional roles. And yet, the traditional view of how inhibitory synapses influences the output of a neuron has been dominated by a ''somatocentric'' perspective, in which the effect of inhibitory inputs is measured by their ability to control somatic membrane potential and the frequency of action potentials initiated in the axon. This classical perspective is based on the passive cable properties of dendrites, which result in spatial attenuation of membrane potential changes and even steeper attenuation of the visibility of a synaptic conductance with distance from the synapse (Koch et al., 1990 ). It's all about location, location, location: the conductance change induced by a single inhibitory synapse remains highly local and reaches its maximum at the site of the synapse, while the best place for an inhibitory synapse to act as a gatekeeper and control the influence of an excitatory synapse on neuronal output is ''on the direct path'' from the excitatory synapse
